HomeCompareBNYN vs JNJ

BNYN vs JNJ: Dividend Comparison 2026

BNYN yields 1052631.58% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNYN wins by $7.963497503125679e+36M in total portfolio value
10 years
BNYN
BNYN
● Live price
1052631.58%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.963497503125679e+36M
Annual income
$7,962,009,567,722,528,000,000,000,000,000,000,000,000,000.00
Full BNYN calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — BNYN vs JNJ

📍 BNYN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNYNJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNYN + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNYN pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNYN
Annual income on $10K today (after 15% tax)
$89,473,684.21/yr
After 10yr DRIP, annual income (after tax)
$6,767,708,132,564,148,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, BNYN beats the other by $6,767,708,132,564,148,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNYN + JNJ for your $10,000?

BNYN: 50%JNJ: 50%
100% JNJ50/50100% BNYN
Portfolio after 10yr
$3.9817487515628397e+36M
Annual income
$3,981,004,783,861,264,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BNYN
No analyst data
Altman Z
-11.4
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNYN buys
0
JNJ buys
0
No recent congressional trades found for BNYN or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNYNJNJ
Forward yield1052631.58%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$7.963497503125679e+36M$30.3K
Annual income after 10y$7,962,009,567,722,528,000,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$7.963400145668761e+36M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BNYN vs JNJ ($10,000, DRIP)

YearBNYN PortfolioBNYN Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$105,273,858$105,263,157.89$10,592$272.30+$105.26MBNYN
2$1,035,762,991,230$1,035,650,348,202.03$11,289$357.73+$1035762.98MBNYN
3$9,524,008,370,109,804$9,522,900,103,709,188.00$12,123$472.89+$9524008370.10MBNYN
4$81,846,272,920,654,280,000$81,836,082,231,698,260,000.00$13,141$629.86+$81846272920654.27MBNYN
5$657,352,099,039,416,200,000,000$657,264,523,527,391,100,000,000.00$14,408$846.81+$657352099039416192.00MBNYN
6$4,934,208,226,426,849,000,000,000,000$4,933,504,859,680,876,000,000,000,000.00$16,021$1,151.60+$4.934208226426849e+21MBNYN
7$34,614,450,996,181,180,000,000,000,000,000$34,609,171,393,378,904,000,000,000,000,000.00$18,122$1,588.22+$3.461445099618118e+25MBNYN
8$226,943,778,760,972,850,000,000,000,000,000,000$226,906,741,298,406,850,000,000,000,000,000,000.00$20,930$2,228.20+$2.2694377876097286e+29MBNYN
9$1,390,593,834,719,905,300,000,000,000,000,000,000,000$1,390,351,004,876,631,000,000,000,000,000,000,000,000.00$24,792$3,191.91+$1.3905938347199052e+33MBNYN
10$7,963,497,503,125,679,000,000,000,000,000,000,000,000,000$7,962,009,567,722,528,000,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$7.963497503125679e+36MBNYN

BNYN vs JNJ: Complete Analysis 2026

BNYNStock

Banyan Corp., through its subsidiaries, engages in the franchising of chiropractic clinics in North America. It provides practice development training and assistance to chiropractors, as well as offers franchise support and related services to franchisees and licensees. The company also offers diagnostic testing services. Banyan Corporation provides nerve conduction velocity (NCV) testing to patients through health care professionals, such as doctors and chiropractors. The NCV testing measures the transmission of nerve impulses through the body, identifies problems in the nervous system, and enables to substantiate the cost of treatment to patients and their insurers. In addition, it manufactures and markets the VT3000, a nerve testing system for the diagnosis of neuropathies, which are diseases of the peripheral nerves and parts of the spine, as well as nerve irritation and other damage to the nervous system of a patient. The company was founded in 1978 and is based in Beverly Hills, California.

Full BNYN Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BNYN vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNYN vs SCHDBNYN vs JEPIBNYN vs OBNYN vs KOBNYN vs MAINBNYN vs ABBVBNYN vs MRKBNYN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.